Home
Clinical Trials
Lisinopril or Coreg CR® in R...

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Last Updated: 2021-03-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

468 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Lisinopril or Coreg CR®, may help reduce side effects caused by trastuzumab. It is not yet known whether lisinopril or Coreg CR® are more effective than a placebo in reducing side effects caused by trastuzumab.

PURPOSE: This phase II trial is studying lisinopril and Coreg CR® to see how well they work compared with a placebo in reducing side effects in patients with HER2-positive breast cancer receiving trastuzumab.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy

NCT05019365

Breast Cancer HER2-positive Breast Cancer Cardiotoxicity

UNKNOWN

Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT00006381

Breast Cancer

COMPLETED PHASE2

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

NCT00005635

Breast Cancer

COMPLETED PHASE2

A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients

NCT03983382

Breast Cancer

ACTIVE_NOT_RECRUITING

Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery

NCT00381901

Breast Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* The primary objective of this study is to determine if administration of lisinopril or Coreg CR®, compared to placebo, will reduce the incidence of trastuzumab-induced cardiotoxicity, as measured by LVEF, in patients receiving adjuvant, or neoadjuvant,therapy for HER2 positive breast cancer.

Secondary

* To determine whether subjects randomized to active agent have fewer interruptions in trastuzumab therapy due to cardiomyopathy.
* To determine whether the treatment effect is consistent in anthracycline and nonanthracycline patient cohorts
* To compare changes in HRQL among the treatment groups during the study intervention
* To evaluate the long term effects on the prevention of cardiomyopathy and impact on HRQL for either or both study agents
* To compare the predictive value of troponin I and BNP in the identification of trastuzumab-induced cardiotoxicity

OUTLINE: This is a multicenter study. Patients are stratified according to chemotherapy comprising an anthracycline (yes vs no). Patients are randomized to 1 of 3 treatment arms.

* Arm I: Patients receive oral lisinopril once daily.
* Arm II: Patients receive oral Coreg CR® once daily.
* Arm III: Patients receive oral placebo once daily.

In all arms, study treatment begins with the first dose of trastuzumab and continues for up to 52 weeks or until the end of trastuzumab therapy.

Quality of life is assessed using the EORTC QLQ-C30 questionnaire at baseline, at 52 weeks (or at the end of trastuzumab therapy), and at 18 and 24 months (or 6 and 12 months after the completion of trastuzumab).

After completion of study treatment, patients are followed up at 3, 6, 9, and 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Cardiac Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I lisinopril

Patients receive oral lisinopril once daily.

Group Type EXPERIMENTAL

lisinopril

Intervention Type DRUG

Given orally

Arm II Coreg CR®

Patients receive oral Coreg CR® once daily.

Group Type EXPERIMENTAL

Coreg CR®

Intervention Type DRUG

Given orally

Arm III placebo

Patients receive oral placebo once daily.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

Given orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coreg CR®

Given orally

Intervention Type DRUG

lisinopril

Given orally

Intervention Type DRUG

placebo

Given orally

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

carvedilol phosphate extended-release Registered Trade names: Prinivil, Tensopril, Zestril, Hipril

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and Females ≥ 18 years old diagnosed with HER2 positive breast cancer
* Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy (anthracycline-containing regimens are permitted). Patients receiving Herceptin® with their chemotherapy are permitted for eligibility work-up. Taxanes are permitted. Trastuzumab (Herceptin®) therapy may be given with or after primary chemotherapy. Pertuzumab may be used in conjunction with trastuzumab.
* Left Ventricular Ejection Fraction (LVEF) ≥ 50% by MUGA scan or echocardiogram
* Adequate renal function for administration of trastuzumab-containing chemotherapy regimen.
* Sitting systolic blood pressure of \> 90 mm Hg
* Pulse ≥ 60 beats/minute
* Not pregnant or breastfeeding
* Female patients of childbearing potential, who are sexually active, must have a negative pregnancy test before starting the study
* Both men and women must be willing to use effective contraception during the study. Teratogenicity is documented for both active study agents
* Able to swallow capsules

Exclusion Criteria

* Patients with metastatic disease
* Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen
* Current treatment with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), such as losartan, β-blockers or digoxin
* Known cardiac history: heart failure, myocardial infarction, radiation-induced cardiac dysfunction
* Known allergy to either ACE inhibitors or β-blockers
* History of bronchial asthma or related bronchospastic conditions
* Hereditary or idiopathic angioedema
* History of severe hypersensitivity reactions to drugs or other causes, i.e. bee stings
* This protocol does not exclude patients who are participating on other investigational studies. Refer to the local IRB guidelines.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maya Guglin, MD, PhD

Role: STUDY_CHAIR

University of South Florida

Pamela N. Munster, MD

Role: STUDY_CHAIR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Todd Cancer Institute at Long Beach Memorial Medical Center

Long Beach, California, United States

Site Status

Olive View - UCLA Medical Center Foundation

Sylmar, California, United States

Site Status

Aurora Presbyterian Hospital

Aurora, Colorado, United States

Site Status

Boulder Community Hospital

Boulder, Colorado, United States

Site Status